Terns Pharmaceuticals EBIT

Terns Pharmaceuticals (TERN) currently reports a EBIT of $-110M as of December 2025. That compares with $-100M in the prior-year period — down 8.1% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Terns Pharmaceuticals's EBIT history and peer comparisons.

Terns Pharmaceuticals's EBIT decreased from $-100M to $-110M — a 8.1% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Terns Pharmaceuticals's EBIT of $-110M is lower than the Healthcare sector average of $23B. That is roughly 100.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Terns Pharmaceuticals reported $-110M in EBIT as of December 2025. That compares with $-100M in the prior-year period — down 8.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-110M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Terns Pharmaceuticals, and consider following TERN for alerts when major investors trade the stock.